Damian CARNELL’s Post

AstraZeneca’s CEO pay proposals for its 11 April 2024 AGM face a shareholder revolt after both ISS And Glass Lewis have recommended a vote against. But given the size and indusrty of AstraZeneca, and its use of, and exposure to the global talent market, particularly the USA the proposal seems to be preventative of trouble ahead, rather than curative of a current pay malaise within the current package. Much medical thinking likes preventative in preference to curative solutions, and so this approach seems reasonable, but the big question remains - is the quantum and mix proposal judged in the round a good move? And all this in the context of the LSE “Big Tent” discussion on UK competitiveness in many dimensions, including that of executive compensation levels and governance. NEWSPOINT takes a closer look… https://lnkd.in/e285CibR #executiveremuneration #LSE #astrazeneca #bigtent #corpgro #corporategrowth

In light of the latest news, AstraZeneca's strategic move to boost drug stockpiles raison d'être is evident. Preparing for a potential no-deal Brexit, it amplifies an undercurrent whisper of uncertainty heard across Europe's marketplaces. Here's the significance of this decision unpacked: • **Judicious Preparedness:** A corporate behemoth like AstraZeneca leading the pack in preparing for an unsavory outcome—hard Brexit—crafts a layered fjord of precautionary preparedness. It is sparking others to reassess and revisit strategies, thus fostering an economic ecosystem bracing itself for turbulence. • **Trust Reinforcement:** Amid spikes in illicit pharmaceutical trade seizing the European Union, this move could shore up users' trust, asserting a robust buffer system's presence to circumvent disruptions. AstraZeneca's commitment to ensuring undisrupted access to medications proves valuable for public faith resurgence. Now, what does the future hold? • **Innovation imperative:** A call to arms for cross-sector innovation is increasingly felt. The counterfeit medicine plague incentivizes a rethink in strategy, unearthing new opportunities for businesses demonstrating ability to pivot, innovate, and adapt. • **Consumer-centric evolution:** The companies critical to public health, such as AstraZeneca, are expected to lead a consumer-centric transition–paving the way to respond proactively to future uncertainties. Life sciences is an arena known for resilience, yet the testing contours of hard Brexit may immeasurably amplify this testimony. Moving next, it’s interesting to observe how businesses reshape their roadmaps to remain buoyant in face of imminent adversities and circumvent risks more astutely. Keep a pulse on what the ramifications of Brexit mean for EU's Life Sciences and Health sector [here](https://lnkd.in/d9tzpiqs). #healthcare #lifesciences #brexit #uncertainty #preparedness #innovation #trust #publichealth #businessstrategy

Record pay to Britian's CEO in 2023 Mr. Pascal Soriot - CEO of AstraZeneca is the highest-paid British CEO with pay of 16.85 million pounds. Next is Mr. Erik Engstrom of information and analytics group RELX earning 13.64 million pounds. The bosses of Britain's biggest companies enjoyed record pay in 2023, with nine firms offering them packages of more than 10 million pounds ($12.75 million). The median pay for a FTSE-100 company CEO rose 2.2% to 4.19 million pounds last year.

In a quiet week, the UK press were kept busy with various rumours about the Spring Budget. We had one contact that suggested this Budget may be the first part of a fiscal trilogy due to the lack of financial wriggle room now. Elsewhere US GBP numbers were good, and the Yen strengthened (which has been a very rare occurrence!). The political football that is the UK housebuilding sector also came under pressure due to a review by the CMA – competition and markets authority. A UK stock market bellwether, Reckitt Benckiser disappointed analysts (and holders) and Direct Line was the latest company to be approached for takeover. Hunting and IMI had decent prints and Frasers Group went shopping! Over the pond Warren Buffett made a tribute to Charlie Munger in Berkshire’s quarterly report. Snowflake’s share price melted as Universal Music hit the right note! (sorry). At the beginning of February, we highlighted some car manufacturers putting the brake on their EV expansion. This week we had a leak from Apple that their “Project Titan” EV project had been parked and Mercedes and Aston Martin both paused their new divisions. Is it simply a battle between Tesla and the Chinese manufacturers, or maybe Frasers (see above) are correct and EVs should stick to Scalextric? The US stock market has the “Magnificent 7.” In Europe, they have the “Granolas” a term coined by Goldman Sachs to describe 11 ascendant European companies that have lifted European markets to a record high. They have contributed half of the Stoxx Europe 600 increase over the last year! #TWTWTW #ThatWasTheWeekThatWas #vermeerpartners #theartofinvestment #granolas #mag7 #ev

Ensuring a stable and reliable supply of essential medications in the U.S. remains a challenge, but new opportunities are emerging right here in St. Louis. This isn’t just about healthcare; it’s about economic growth, workforce development, and community impact. We hope you can join us and be part of the solution. #PharmaInnovation #WorkforceDevelopment #EconomicGrowth #MissouriInnovation #STL https://lnkd.in/gSrjq-64

Investigate Europe analysed the last five years of accounts filed by the 15 largest American and European pharmaceutical groups and found 1,300 subsidiaries in hashtag #taxhavens. The true number is likely higher, as reporting rules force multinationals to only list “significant undertakings. This fortune amassed by big pharma in Europe is in stark contrast with local access inequality and struggling healthcare budgets. Such is the case for Ireland, where despite luring drugmakers with its fiscal perks, Irish patients are often waiting longer than their western European peers to get innovative and lifesaving drugs. Our investigation hashtag #Deadlyprices looks into how big pharma feeds inequality in Europe. Stay up to date and read more here: https://bit.ly/3WtnCzq

𝗧𝗼𝗱𝗮𝘆 𝘁𝗵𝗲 𝗺𝗶𝗻𝗶 #𝗔𝗣𝗔𝗖𝗧 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝘀𝘁𝗮𝗿𝘁𝘀 𝗶𝗻 𝗠𝗮𝗰𝗰𝗹𝗲𝘀𝗳𝗶𝗲𝗹𝗱, 𝗨𝗞! Meet there our experts from Hellma UK Limited and Marilena Pagano.   Get some interesting insights about "Advances in Process Analytics and Control Technologies".

📈 Abbott (ABT) Outperforms Market Expectations! 🌟 Great news for investors and stakeholders! Abbott (ABT) has exceeded market returns, showcasing its resilience and robust performance in the healthcare sector. 🌐 Key Highlights: -Abbott's strategic initiatives and innovative product launches have driven this impressive growth. -Consistent focus on expanding their medical device and diagnostics portfolios has paid off significantly. -The company's strong financial performance is a testament to its commitment to improving global health. -This achievement underscores Abbott's position as a leader in the healthcare industry, continuously delivering value to its shareholders and making impactful contributions to medical advancements. 🚀 Let's celebrate this milestone and look forward to more groundbreaking achievements from Abbott! #Abbott #MarketPerformance #HealthcareInnovation #InvestmentSuccess #MedicalDevices #Diagnostics #GlobalHealth #FinancialGrowth #StockMarket #InvestorNews

How can Pharma and Medtech companies motivate positive change and drive transformation across the NHS? Join us on Tuesday 5th November 2024 in Manchester, where we will be exploring: 💡 How industry can support the NHS to improve pathways and optimise patient care 💡 How drivers and barriers for change fit within the national policy context 💡 How services are shifting across acute and community care, and what Pharma and Medtech can do to ensure product update in the most appropriate settings These themes will be explored in our opening sessions and afternoon breakout discussions by our guest speakers: 🎤 Professor Hilary Garratt CBE (ICB NHS Non-Executive Director, Accredited Senior Executive Coach and Mentor); and 🎤 Dr Raj Patel MBE (Former Senior Medical Director in NHS England, NHS Transformation Consultant) These sessions will be interspersed with sessions on specialised commissioning, finance, and government policy (where we will discuss the Darzi report and other key policies). Market access and NHS engagement leads from across the industry are attending, will you be there? Book now at: https://lnkd.in/e6uMKdGJ #NHStransformation #marketaccess #NHSinsights #NHSwhispers #pharma #pharmaceutical #medtech #medicaldevices

#Pharma and #healthcare companies are eager to get deals done as they grow more comfortable navigating the current environment of elevated interest rates and regulatory pressure. Read more in the PwC UK M&A trends report  https://pwcuk.smh.re/kDD  #PwCDeals #IndustryTrends